比亚迪联合创始人，即将收获又一家IPO！

Core Viewpoint - Anuo Youda, an IVD medical device company, has officially begun its journey to list on the Hong Kong Stock Exchange, backed by founder Xia Zuoquan, who is also a co-founder of BYD and an angel investor in UBTECH [1][2]. Company Overview - Anuo Youda was established in April 2012 and focuses on molecular diagnostics and IVD medical devices, particularly in non-invasive prenatal testing (NIPT) [5][6]. - The company has developed a comprehensive IVD product portfolio, including NIPT kits that received regulatory approval in 2017, positioning it as a leader in the prenatal testing market in China [6][9]. Market Position - As of 2023, Anuo Youda ranks third in the Chinese NIPT market, with market shares increasing from 9.6% in 2021 to 12.1% in 2023 [6][9]. - The company has expanded its customer base significantly, selling IVD products to 86 hospitals certified for prenatal diagnosis across 26 provinces, up from 61 hospitals in 2023 [9]. Financial Performance - Anuo Youda reported revenues of RMB 4.35 billion, RMB 4.75 billion, and RMB 5.18 billion for the years 2022, 2023, and 2024, respectively, while still operating at a loss [9][10]. - The losses for the same years were RMB 668.1 million, RMB 240.2 million, and RMB 125.8 million, indicating a trend of increasing revenue but persistent financial challenges [9][10]. Shareholder Structure - Xia Zuoquan controls 54.25% of the voting rights in Anuo Youda, with a strong backing from notable investors such as China Life, Northern Light Venture Capital, and others [11][14]. - The company has a robust shareholder base that provides financial support and strategic guidance, enhancing its growth prospects [14]. Management Team - The management team is led by CEO Li Zhimin, who has over 30 years of experience in the pharmaceutical and medical industries, bringing valuable insights and relationships to the company [19].